Peptides
GLP-1s Beyond Diabetes: New Meta-Analysis Maps Cardiovascular and Gynecologic Frontiers
A 2025 meta-analysis of 29 randomized trials suggests GLP-1 receptor agonists trim cardiovascular events in non-diabetic adults with obesity — while parallel reviews push the class into PCOS, perioperative care, and an experimental dual-receptor frontier.